^
    Back
    Association details:
    Biomarker:HMOX1 expression
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Onco Targets Ther
    Title:

    Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib

    Excerpt:
    ...for both sorafenib- or sunitinib-treated patients, the CBR of low HO-1 expression was significantly higher than the CBR of high HO-1 expression. The results showed that the HO-1 expression level is significantly associated with sensitivity to sorafenib and sunitinib.
    DOI:
    10.2147/OTT.S86222